TY - JOUR
T1 - Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer
T2 - An Individual Patient-level Meta-analysis of Six Randomized Trials
AU - Kishan, Amar U.
AU - Chu, Fang I.
AU - King, Christopher R.
AU - Seiferheld, Wendy
AU - Spratt, Daniel E.
AU - Tran, Phuoc
AU - Wang, Xiaoyan
AU - Pugh, Stephanie E.
AU - Sandler, Kiri A.
AU - Bolla, Michel
AU - Maingon, Philippe
AU - De Reijke, Theo
AU - Nickols, Nicholas G.
AU - Rettig, Matthew
AU - Drakaki, Alexandra
AU - Liu, Sandy T.
AU - Reiter, Robert E.
AU - Chang, Albert J.
AU - Feng, Felix Y.
AU - Sajed, Dipti
AU - Nguyen, Paul L.
AU - Kupelian, Patrick A.
AU - Steinberg, Michael L.
AU - Boutros, Paul C.
AU - Elashoff, David
AU - Collette, Laurence
AU - Sandler, Howard M.
N1 - Publisher Copyright:
© 2019 European Association of Urology
PY - 2020/2
Y1 - 2020/2
N2 - Background: The importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown. Objective: To evaluate the clinical implications of LF after definitive RT. Design, setting, and participants: Individual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials. Outcome measurements and statistical analysis: Multivariable Cox proportional hazard models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), and distant metastasis (DM)-free survival (DMFS) and LF as a time-dependent covariate. Markov proportional hazard models were developed to evaluate the impact of specific transitions between disease states on these endpoints. Results and limitations: Median follow-up was 6.4 yr overall and 7.2 yr for surviving patients. LF was significantly associated with OS (hazard ratio [HR] 1.70 [95% confidence interval {CI} 1.37–2.10]), PCSS (3.10 [95% CI 2.33–4.12]), and DMFS (HR 1.92 [95% CI 1.54–2.39]), p < 0.001 for all). Patients who had not transitioned to the LF state had a significantly lower hazard of transitioning to a PCa-specific death state than those who transitioned to the LF state (HR 0.13 [95% CI 0.04–0.41], p < 0.001). Additionally, patients who transitioned to the LF state had a greater hazard of DM or death (HR 2.46 [95% CI 1.22–4.93], p = 0.01) than those who did not. Conclusions: LF is an independent prognosticator of OS, PCSS, and DMFS in high-grade localized PCa and a subset of DM events that are anteceded by LF events. LF events warrant consideration for intervention, potentially suggesting a rationale for upfront treatment intensification. However, whether these findings apply to all men or just those without significant comorbidity remains to be determined. Patient summary: Men who experience a local recurrence of high-grade prostate cancer after receiving upfront radiation therapy are at significantly increased risks of developing metastases and dying of prostate cancer. Using individual patient-level data from six randomized trials, we have found that local failure events after definitive radiotherapy for high-grade prostate cancer are independent, significant predictors of distant metastasis–free survival, prostate cancer–specific survival, and overall survival. Using multistate modeling, we identify that most distant metastatic events occur from an apparent disease-free state, but an increasing proportion occurs over time subsequent to local failure events.
AB - Background: The importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown. Objective: To evaluate the clinical implications of LF after definitive RT. Design, setting, and participants: Individual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials. Outcome measurements and statistical analysis: Multivariable Cox proportional hazard models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), and distant metastasis (DM)-free survival (DMFS) and LF as a time-dependent covariate. Markov proportional hazard models were developed to evaluate the impact of specific transitions between disease states on these endpoints. Results and limitations: Median follow-up was 6.4 yr overall and 7.2 yr for surviving patients. LF was significantly associated with OS (hazard ratio [HR] 1.70 [95% confidence interval {CI} 1.37–2.10]), PCSS (3.10 [95% CI 2.33–4.12]), and DMFS (HR 1.92 [95% CI 1.54–2.39]), p < 0.001 for all). Patients who had not transitioned to the LF state had a significantly lower hazard of transitioning to a PCa-specific death state than those who transitioned to the LF state (HR 0.13 [95% CI 0.04–0.41], p < 0.001). Additionally, patients who transitioned to the LF state had a greater hazard of DM or death (HR 2.46 [95% CI 1.22–4.93], p = 0.01) than those who did not. Conclusions: LF is an independent prognosticator of OS, PCSS, and DMFS in high-grade localized PCa and a subset of DM events that are anteceded by LF events. LF events warrant consideration for intervention, potentially suggesting a rationale for upfront treatment intensification. However, whether these findings apply to all men or just those without significant comorbidity remains to be determined. Patient summary: Men who experience a local recurrence of high-grade prostate cancer after receiving upfront radiation therapy are at significantly increased risks of developing metastases and dying of prostate cancer. Using individual patient-level data from six randomized trials, we have found that local failure events after definitive radiotherapy for high-grade prostate cancer are independent, significant predictors of distant metastasis–free survival, prostate cancer–specific survival, and overall survival. Using multistate modeling, we identify that most distant metastatic events occur from an apparent disease-free state, but an increasing proportion occurs over time subsequent to local failure events.
KW - High grade
KW - Local failure
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85075335483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075335483&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2019.10.008
DO - 10.1016/j.eururo.2019.10.008
M3 - Article
C2 - 31718822
AN - SCOPUS:85075335483
SN - 0302-2838
VL - 77
SP - 201
EP - 208
JO - European Urology
JF - European Urology
IS - 2
ER -